Exagen Inc. (XGN)
XGNNASDAQ-GMMedical Specialities
$5.58
+0.3245 (+6.17%) today
At the close, Nov 10, 4:00 PM ET. Pre-market $5.55 +5.51%
- Market cap
- $134.45m
- P/E
- –
- EPS, last 4 quarters
- $-0.7500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.59 to $9.74
- Average volume
- 367.9k
- Previous close
- $5.26
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $10.40, +86.2% from here
Earnings
next estimate $-0.1900Next report
Dec 2025
0.0%
Mar 2026
+29.2%
Jun 2026
+31.6%
Sep 2026
-31.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $17.24m | $16.63m | $17.31m | $19.94m |
| Gross profit | $10.07m | $9.21m | $10.21m | $12.22m |
| Operating income | -$3.10m | -$4.97m | -$3.41m | -$1.72m |
| Net income | -$7.09m | -$4.67m | -$3.97m | -$3.20m |
Last four quarters: revenue $71.12m, margin -26.6%, free cash flow -$7.59m
News
8 latest- Exagen (XGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 17 hours ago
- Exagen Inc Q3 Loss Drops RTTNews · 1 day ago
- Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue EstimatesZacks · 1 day ago
- Exagen is Now Oversold (XGN)BNK Invest · 5 days ago
- Nephros Inc. (NEPH) Tops Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat EstimatesZacks · Nov 4, 2026
- Exagen (XGN) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 11, 2026
- Exagen Q2 Earnings Call HighlightsMarketBeat · Aug 4, 2026
The company
Exagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- exagen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.